Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinomas of the human breast

Folia Morphologica

Volumn 68, Issue 3, 2009, Pages 144-155

  Safwat, M D ^a   Habib, F ^b   Elayat, A ^a   Oweiss, N ^c   Reffat, S ^d   Algaidi, S ^a  

^a Faculty of Medicine Anatomy   (Saudi Arabia)

^b Faculty of Medicine Obstetrics and Gynaecology   (Saudi Arabia)

^c Faculty of Medicine Pathology   (Saudi Arabia)

^d Faculty of Medicine Surgery   (Saudi Arabia)

Author keywords

Cancer; CD105; CD34; Computer image analysis; MVD; VEGF

Indexed keywords

CD34 ANTIGEN; ENDOGLIN; MONOCLONAL ANTIBODY; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MORPHOMETRICS; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

ADULT; ANTIGENS, CD; ANTIGENS, CD34; BLOOD VESSELS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE PROGRESSION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350046449     PISSN: 00155659     EISSN: 16443284     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, Cairnduff F, Selby PJ, Perren TJ, Lansdown M, Banks RE (2000) Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res, 60: 2898-2905 (Pubitemid 30395813)
2. Al-Harris ES, Al-Janabi AA, Al-Toriahi KM, Yasseen AA (2008) Over expression of vascular endothelial growth factor in correlation to Ki-67, grade, and stage of breast cancer. Saudi Med J, 29: 1099-1104.
3. Beresford MJ, AL Harris ES, Ah-See M, Daley F, Padhani AR, Makris A (2006) The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br J Cancer, 95: 1683-1688. (Pubitemid 44950794)
4. Bocci G, Fasciani A, Danesi R, Viacava P, Genazzani AR, Del Tacca M (2001) In-vitro evidence of autocrine secretion of vascular endothelial growth factor by endothelial cells from human placental blood vessels. Mol Hum Reprod, 7: 771-777.
5. Bolat F, Kayaselcuk F, Nursal TZ, Yagmurdur MC, Bal N, Demirhan B (2006) Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J Exp Clin Cancer Res, 25: 365-372. (Pubitemid 44763728)
6. Brekken RA, Li C, Kumar S (2002) Strategies for vascular targeting in tumours. Int J Cancer, 100: 123-130.
7. Brewer CA, Setterdahl JJ, Li MJ, Johnston JM, Mann JL, Mcasey ME (2000) Endoglin expression as a measure of microvessel density in cervical cancer. Obstetrics Gynecol, 96: 224-228.
8. Callagy G, Dimitriadis E, Harmey J, Bouchier-Hayes D, Leader M, Kay E (2000) Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer. A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor. Appl Immurvival nohistochem Mol Morphol, 8: 104-109.
9. Charpin C, Dales JP, Garcia S, Carpentier S, Djemli A, Andrac L, Lavaut MN, Allasia C, Bonnier P (2004) Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. Clin Cancer Res, 10: 5815-5819. (Pubitemid 39180960)
10. Charpin-Taranger C, Dales JP, Garcia S, Andrac-Meyer L, Ramuz O, Carpentier-Meunier S, Bonnier P (2003) The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers. Bull Acad Natl Med, 187: 1129-1145.
11. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Charpin C (2004) Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol, 35: 176-183.
12. Ding S, Li C, Lin S, Yang Y, Liu D, Han Y, Zhang Y, Li L, Zhou L, Kumar S (2003) Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Human Pathol, 37: 861-866. (Pubitemid 43902946)
13. Dromain C, Balleyguier C, Muller S, Mathieu MC, Rochard F, Opolon P, Sigal R (2006) Evaluation of tumor angiogenesis of breast carcinoma using contrast-enhanced digital mammography. Am J Roentg, 187: W528-W537.
14. Du JR, Jiang Y, Zhang YM, Fu H (2003) Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas. World J Gastroenterol, 9: 1604-1606. (Pubitemid 36992365)
15. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19: 403-410.
16. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med, 9: 669-676.
17. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American pathologists consensus statement. Arch Pathol Lab Med, 124: 966-978.
18. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med, 285: 1182-1186.
19. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M (2003) Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene, 22: 6557-6563. (Pubitemid 37372335)
20. Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M (2003) Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets, 3: 427-432. (Pubitemid 38017479)
21. Gabriel CN, Cristina BB, Arlete H, Lígia Maria BC (2008) Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105//endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas. Neuropathology, 28: 17-23.
22. Gasparini G (2000) Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist, 5: 37-44.
23. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N (2005) Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer, 5: 25.
24. Kohlberger P, Obermair A, Sliutz G, Heinzl H, Koelbl H, Breitenecker G, Gitsch G, Kainz C (1996) Quantitative immunohistochemistry of factor-VIII-related antigen in breast carcinoma. Am J Clin Pathol, 105: 705-710.
25. Naccarato AG, Viacava P, Bocci G, Fanelli G, Aretini P, Lonobile A, Montruccoli G, Bevilacqua G (2003) Definition of the microvascular pattern of the normal human adult mammary gland. J Anat 203: 599-603.
26. Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, Nawaz S (2007) Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer, 97: 391-397.
27. Parkin DM, Fernandez LM (2006) Use of statistics to assess the global burden of breast cancer. Breast J, 12: 70-80.
28. Safwat MD, Habib FA, Oweiss NY, Bassyoni SA (2008) The microvasculature of the normal and pathological human adult mammary gland. New Egypt J Med, 38: 207-219.
29. She X, Matsuno F, Haradan N, Tsai H, Seon BK (2004) Synergy between anti-endolgin (CD 105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer, 108: 251-257. (Pubitemid 37541779)
30. Simpson JF, Ahn C, Battifora H, Esteban JM (1996) Endothelial area as a prognostic indicator for invasive breast carcinoma. Cancer, 77: 2077-2085. (Pubitemid 26142052)
31. Tafuri LSA, Rocha GFS, Gobbi H (2006) Cell cycle related proteins in hyperplasia of usual type in breast specimens of patients with and without breast cancer. BMC Cell Biol, 7: 29.
32. Teo NB, Shoker BS, Jarvis C, Martin L, Sloane JP, Holcombe C (2002) Vascular density and phenotype around ductal carcinoma in situ (DCIS) of the breast. Br J Cancer, 86: 905-911. (Pubitemid 34271026)
33. Uzzan B, Nicolas P, Cucherat M, Perret GY (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res, 64: 2941-2955. (Pubitemid 38581387)
34. Viacava P, Gasperi M, Acerbi G, Manetti L, Cecconi E, Naccarato AF (2003) Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest, 26: 23-28. (Pubitemid 36292248)
35. Viacava P, Naccarato AG, Bocci G, Fanelli G, Aretini P, Lonobile A, Evangelista G, Montruccoli G, Bevilacqua G (2004) Angiogenesis and VEGF expression in preinvasive lesions of the human breast. J Pathol, 204: 140-146. (Pubitemid 39335286)
36. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD (1993) A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer, 54: 363-370. (Pubitemid 23169671)
37. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med, 324: 1-8.
38. Wei-guo X, Gang W, Yu-huan Z, Ji-ning S, Xiao-qing Y, Wen-ya W (2007) Vascular endothelial growth factor expression in invasive ductal carcinoma of breast. Chin J Cancer Res, 19: 56-59. (Pubitemid 46569447)
39. Yang LY, Lu WQ, Huang GW, Wang W (2006) Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer, 6: 110-1108
40. Yasukawa T, Kimura H, Tabata Y, Miyamoto H, Honda Y, Ikada Y, Ogura Y (2000) Active drug targeting with immunoconjugates to choroidal neovascularization. Curr Eye Res, 21: 952-961. (Pubitemid 32452708)
41. Zhou S, Wang GP, Liu C, Zhou M (2006) Eukaryotic Initiation Factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer. BMC Cancer, 6: 231. (Pubitemid 44566740)